This activity is supported by an educational grant from:




Provided by:

Improving Members' Outcomes Across the Continuum of Diabetes:
Assessing the Impact of New Measures, Technologies, and Benefit Design Strategies

Program Faculty:

Chair
Lawrence Blonde, MD, FACP, FACE
Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolism
Associate Internal Medicine Residency Program Director
Ochsner Clinic Foundation
New Orleans, LA

Speakers
Andrew J. Ahmann, MD, MS
Associate Professor of Medicine
Oregon Health and Science University
Medical Director, Diabetes Care Center
Portland, OR

Jan Berger, MD, MJ
Senior Vice President, Chief Clinical Officer
Caremark, Inc.
Northbrook, IL

Curtis L. Triplitt, PharmD, CDE
Assistant Professor
Department of Medicine, Division of Diabetes
University of Texas Health Science Center at San Antonio and Texas Diabetes Institute
San Antonio, TX


Activity Overview:

This activity provides participants with an update on diabetes in the United States, discusses new and investigational pharmacotherapeutic agents and technologies in diabetes treatment, and evaluates and debates new benefit design strategies and their potential application to this disease state.


Educational Objectives:

1. Describe current gaps in the management of diabetes in the US healthcare system, given current prevalence and epidemiologic data.
2. Define current standards of care for the management of diabetes, based on consensus recommendations from professional associations and societies.
3. Identify members who can be appropriately treated with new and emerging diabetes technologies and classes of medications.
4. Analyze the potential impact of novel pharmacy benefit designs in the area of diabetes management, given experiential data from a large employer.
   

Target Audience:

This activity is for managed healthcare professionals with an interest in improving members' outcomes in diabetes through the appropriate use of new technologies and innovative benefit design strategies.

Faculty Disclosure:

It is the policy of the Bimark Center for Medical Education (BCME) to require the disclosure of any financial relationships or other relationships that a faculty member has with the manufacturers of any commercial products or providers relevant to the topics or therapeutic areas being discussed.

Andrew J. Ahmann, MD, MS

Consultant: The Amylin-Lilly Alliance; Ortho-Clinical Diagnostics; sanofi-aventis

Speaker: The Amylin-Lilly Alliance; Novo Nordisk; sanofi-aventis


Jan Berger, MD, MJ

Stockholder/Employee: Caremark, Inc.


Lawrence Blonde, MD, FACP, FACE

Consultant and Speaker: Abbott Laboratories; Amylin Pharmaceuticals; Eli Lilly and Company; GlaxoSmithKline; Lifescan, Inc.; Merck/Schering-Plough; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis

Consultant: AstraZeneca Pharmaceuticals LP

Research Funding: Amylin Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; MannKind Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; sanofi-aventis

Speaker: Takeda Pharmaceuticals North America, Inc.; Wyeth Pharmaceuticals


Curtis L. Triplitt, PharmD, CDE

Advisory Board: Amylin Pharmaceuticals

Speaker: Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis


BCME staff involved in clinical content development have no relevant financial relationships to disclose.


Unlabeled/Unapproved Uses Notice:

In accordance with the BCME policy, the audience is advised that one or more presentations in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices.


Commercial Support:

This activity is supported by an educational grant from Amylin Pharmaceuticals and Eli Lilly and Company.